Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

Vaccine

Volumn 29, Issue 46, 2011, Pages 8417-8428

  Bakari, Muhammad ^a   Aboud, Said ^a,b   Nilsson, Charlotta ^b,c   Francis, Joel ^d   Buma, Deus ^e   Moshiro, Candida ^a   Aris, Eric A ^e   Lyamuya, Eligius F ^a   Janabi, Mohamed ^e   Godoy Ramirez, Karina ^c   Joachim, Agricola ^a,b   Polonis, Victoria R ^e   Bråve, Andreas ^c   Earl, Patricia ^g   Robb, Merlin ^h   Marovich, Mary ^f   Wahren, Britta ^b,c   Pallangyo, Kisali ^a   Biberfeld, Gunnel ^b,c   Mhalu, Fred ^a   Sandström, Eric ^b   more..

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d NATIONAL INSTITUTE OF MEDICAL RESEARCH   (Tanzania)

^e MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

DNA prime; HIV vaccine; MVA boost

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS 1 RECOMBINANT MODIFIED VACCINIA VIRUS ANKARA; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; PLASMID DNA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ACUTE GASTROENTERITIS; ADULT; ANUS FISSURE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLADISTICS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; EPISTAXIS; FEMALE; HEAD INJURY; HEADACHE; HEMATEMESIS; HEMOPTYSIS; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; INJECTION SITE PAIN; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MUSCULOSKELETAL CHEST PAIN; NORMAL HUMAN; PARALYTIC ILEUS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TANZANIA; VIRUS GENE; VIRUS NEUTRALIZATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS VACCINES; CELL PROLIFERATION; DRUG CARRIERS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GENETIC VECTORS; HIV-1; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, INTRADERMAL; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; NEUTRALIZATION TESTS; PLACEBOS; PLASMIDS; TANZANIA; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL PROTEINS; VIRAL VACCINES; YOUNG ADULT;

EID: 80053948074     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.001     Document Type: Article

References (56)

1. UNAIDS. UNAIDS report on the global AIDS epidemic; 2010. Available from: http://www.unaids.org/globalreport/Global_report.htm.
2. Paris R.M., Kim J.H., Robb M.L., Michael N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev Vaccines 2010, 9(9):1055-1069.
3. Gilbert P.B., Peterson M.L., Follmann D., Hudgens M.G., Francis D.P., Gurwith M., et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005, 191(5):666-677.
4. Phogat S., Wyatt R.T., Karlsson Hedestam G.B. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Intern Med 2007, 262(1):26-43.
5. Robinson H.L., Amara R.R. T cell vaccines for microbial infections. Nat Med 2005, 11:S25-S32.
6. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006, 312(5779):1530-1533.
7. Mäkitalo B., Lundholm P., Hinkula J., Nilsson C., Karlen K., Morner A., et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004, 85(Pt8):2407-2419.
8. Kim J.H., Rerks-Ngarm S., Excler J.L., Michael N.L. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010, 5(5):428-434.
9. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(12):1650-1660.
10. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective adenovirus vector. J Infect Dis 2006, 194(12):1638-1649.
11. Catanzaro A.T., Roederer M., Koup R.A., Bailer R.T., Enama M.E., Nason M., et al. Phase 1 clinical evaluation of a six-plasmid multiclade HIV-1 DNA vaccine candidate. Vaccine 2007, 25(20):4085-4092.
12. IAVI. Available from: http://www.iavireport.org/trialsdb.
13. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8_ T-cell epitopes. J Virol 2006, 80:4717-4728.
14. Jaoko W., Nakwagala F.N., Anzala O., Manyonyi G.O., Birungi J., Nanvubya A., et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 2008, 26(22):2788-2795.
15. Harari A., Bart P.A., Stöhr W., Tapia G., Garcia M., Medjitna-Rais E., et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 2008, 205(1):63-77.
16. McCormack S., Stohr W., Barber T., Bart P.A., Harari A., Moog C., et al. EV02: a phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine 2008, 26(25):3162-3174.
17. Sandström E., Nilsson C., Hejdeman B., Brave A., Bratt G., Robb M., et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008, 198(10):1482-1490.
18. Koup R.A., Roederer M., Lamoreaux L., Fischer J., Novik L., Nason M.C., et al. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS One 2010, 5(2):e9015. 10.1371/journal.pone009015.
19. Kibuuka H., Kimutai R., Maboko L., Sawe F., Schunk M.S., Kroidl A., et al. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV172). J Infect Dis 2010, 201(4):600-607.
20. Vasan S., Schlesinger S.J., Huang Y., Hurley A., Lombardo A., Chen Z., et al. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One 2010, 5(1):e8617.
21. Ramanathan V.D., Kumar M., Mahalingam J., Sathyamoorthy P., Narayanan P.R., Solomon S., et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses 2009, 25(11):1107-1116.
22. Currier J.R., Ngauy V., de Souza M.S., Ratto-Kim S., Cox J.H., Polonis V.R., et al. Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia-Anlara-HIV-1 vaccine candidate. PLoS One 2010, 5(11):e13983.
23. Vasan S., Schlesinger S.J., Chen Z., Hurley A., Lombardo A., Than S., et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS One 2010, 5(1):e8816.
24. Goepfert P.A., Elizaga M.L., Sato A., Qin L., Cardinali M., Hay C.M., et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011, 203(March (5)):610-619.
25. Ramanathan VD, Mehendale S, Sahay S, Thakar M, Makeshkumar M, Sathyamurthi P, et al. Safety and immunogenicity of DNA prime and modified vaccinia Ankara virus HIV subtype C vaccine boost in Indian volunteers. AIDS vaccine 2010, Atlanta, GA, USA, 28 September-1 October 2010. AIDS Res Hum Retroviruses 26(10):A-1-184.
26. Ross A.L., Brave A., Scarletti G., Manrique A., Buonaguro L. Progress towards development of an HIV vaccine: report of the AIDS vaccine 2009 conference. Lancet Infect Dis 2010, 10(5):305-316.
27. Buchbinder S.P., Mehrotra D.V., Duerr A., Fitzgerald D.W., Mogg R., Li D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomized, placebo-controlled, test-of-concept trial. Lancet 2008, 372(9653):1881-1893.
28. D'souza M.P., Frahm N. Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 2010, 24(6):803-809.
29. HVTN 505. Available from: http://clinicaltrials.gov/ct2/show/NCT00865566.
30. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006, 194:1661-1671.
31. Rerks-Ngarm S., Pitisuttihum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361(23):2209-2220.
32. Bakari M., Lyamuya E., Mugusi F., Aris E., Chale S., Magao P., et al. The prevalence and incidence of HIV-1 infection and syphilis in a cohort of police officers in Dar es Salaam, Tanzania: a potential population for HIV vaccine trials. AIDS 2000, 14(3):313-320.
33. Mosha F., Urassa W., Aboud S., Lyamuya E., Sandstrom E., Bredell H., et al. Prevalence of genotypic resistance to antiretroviral drugs in treatment-naïve youths infected with diverse HIV type 1 subtypes and recombinant forms in Dar es Salaam, Tanzania. AIDS Res Hum Retroviruses 2010, [Epub October 18, 2010].
34. Arroyo M.A., Hoelscher M., Sanders-Buell E., Herbinger K.H., Samky E., Maboko L., et al. HIV type 1 subtypes among blood donors in the Mbeya region of Southwest Tanzania. AIDS Res Hum Retroviruses 2004, 20:895-901.
35. Bråve A., Ljungberg K., Boberg A., Rollman E., Isaguliants M., Lundgren B., et al. Multigene/multi-clade HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 2005, 12(6):1197-1205.
36. Bråve A., Boberg A., Gudmundsdotter L., Rollman E., Hallermalm K., Ljungberg K., et al. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1 specific CD8+ T-cell and humoral responses in mice. Mol Ther 2007, 15(9):1724-1733.
37. Ljungberg K., Rollman E., Eriksson L., Hinkula J., Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002, 302(1):44-57.
38. Bråve A., Ljungberg K., Boberg A., Rollman E., Engstrom G., Hinkula J., et al. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 2006, 24(21):4524-4526.
39. Earl P.L., Cotter C., Moss B., VanCott T., Currier J., Eller L.A., et al. Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine 2009, 27(42):5885-5895.
40. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 2004, 43:1503-1510.
41. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., et al. Incidence and follow-up of inflammatory cardiac complication s after smallpox vaccination. J Am Coll Cardiol 2004, 44:201-205.
42. Nilsson C., Aboud S., Karlén K., Hejdeman B., Urassa W., Biberfeld G. Optimal blood mononuclear cell isolation procedures for gamma interferon enzyme-linked immunospot testing of healthy Swedish and Tanzanian subjects. Clin Vaccine Immunol 2008, 15(4):585-589.
43. Currier J.R., Kuta E.G., Turk E., Earhart L.B., Loomis-Price L., Janetzki S., et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260(1-2):157-172.
44. Aboud S., Nilsson C., Karlén K., Marovich M., Wahren B., Sandstrom E., et al. Strong HIV-specific CD4+ and CD8+ T lymphocyte proliferative responses in healthy individuals immunized with a HIV-1 DNA vaccine and boosted with HIV-1 recombinant modified vaccinia virus Ankara (MVA). Clin Vaccine Immunol 2010, 17(7):1124-1131.
45. Aboud S., Urassa W., Lyamuya E., Mhalu F., Biberfeld G. Evaluation of HIV antibody and antigen/antibody combination ELISAs for use in an alternative confirmatory HIV testing strategy in Dar es Salaam, Tanzania. J Virol Methods 2006, 135(2):192-196.
46. Montefiori D.C. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2004, [chapter 12: unit 11-12].
47. Edmonds T.G., Ding H., Yuan X., Wei Q., Smith K.S., Conway J.A., et al. Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 2010, 408:1-13.
48. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27(33):4468-4474.
49. Tavel J.A., Martin J.E., Kelly G.G., Enama M.E., Shen J.M., Gomez P.L., et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1 seronegative subjects. J Acquir Immune Defic Syndr 2007, 44(5):601-605.
50. Raviprakash K., Porter K.R. Needle-free injection of DNA vaccines: a brief overview and methodology. Methods Mol Med 2006, 127:83-89.
51. Nicolas J.-F., Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7(8):1201-1214.
52. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78(23):13232-13252.
53. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 2005, 79(10):6089-6101.
54. Choudhry V., Zhang M.Y., Sidorov I.A., Louis J.M., Harris I., Dimitrov A.S., et al. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007, 363(1):79-90.
55. Polonis V.R., Brown B.K., Borges A.R., Zolla-Pazner S., Dimitrov D.S., Zhang M.Y., et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008, 375:315-320.
56. Tarimo E.A., Thorson A., Bakari M., Mwami J., Sandstrom E., Kulane A. Willingness to volunteer in a phase I/II HIV vaccine trial: a study among police officers in Dar es Salaam, Tanzania. Glob Health Action 2009, 2. 10.3402/gha.v2i0.1953.